中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(3): 601-605

Effect of entecavir antiviral therapy on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after transcatheter arterial chemoembolization

DOI: 10.3969/j.issn.1001-5256.2021.03.019
  • 1.

    Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

  • 2.

    Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518133, China

  • Received Date: 2020-09-14
  • Accepted Date: 2020-09-29
  • Published Date: 2021-03-20
    Abstract
  •   Objective  To investigate the effect of entecavir (ETV) antiviral therapy on the prognosis of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolization (TACE).  Methods  A total of 170 HCC patients who received TACE for the first time in Liver Cancer Center of Nanfang Hospital from January 2011 to March 2018 were enrolled, among whom 114 patients were treated with ETV (ETV treatment group) and 56 patients did not receive antiviral therapy (control group). Baseline demographic data, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), albumin (Alb), platelet count (PLT), Child-Pugh class, HBeAg and HBV DNA levels, alpha-fetoprotein, and BCLC stage were recorded before treatment, and the changes in HBV DNA level, ALT, AST, TBil, Alb, and Child-Pugh class were observed at weeks 4-8 after treatment; long-term survival was also observed after treatment. Short- and long-term clinical benefits (overall survival) were observed for all patients. The t-test or the Mann-Whithey U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. Multivariate logistic regression analyses were performed for related clinical indices before treatment to identify the risk factors for HBV reactivation. The Kaplan-Meier method was used to analyze the survival curves of overall survival, and the log-rank test was used for comparison of survival curves.  Results  There was no significant difference in the incidence rate of HBV reactivation between the ETV treatment group and the control group (15.79% vs 16.07%, χ2=0.002, P=0.962). The univariate analysis showed that PLT was a risk factor for HBV reactivation (Z=-2.183, P=0.029), and the multivariate analysis showed that HBV DNA level was an independent risk factor for HBV reactivation (hazard ratio =1.000, P=0.015). The 1-, 3-, and 5-year survival rates were 56.20%, 30.30%, and 13.20%, respectively, in the ETV treatment group and 60.60%, 27.20%, and 16.30%, respectively, in the control group. There was no significant difference in overall survival rate between the two groups (χ2=0.049, P=0.755).  Conclusion  Antiviral therapy can inhibit HBV replication after TACE in patients with HBV-related HCC, thereby reducing the hepatotoxicity of TACE.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
    [2]
    VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263
    [3]
    VERSLYPE C, ROSMORDUC O, ROUGIER P, et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23(Suppl 7): vii41-48. http://www.biomedcentral.com/pubmed/22997452
    [4]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. DOI: 10.1007/s12072-017-9799-9
    [5]
    WANG K, JIANG G, JIA Z, et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative[J]. Medicine (Baltimore), 2018, 97(22): e10940. DOI: 10.1097/MD.0000000000010940
    [6]
    LIN XJ, LAO XM, SHI M, et al. Changes of HBV DNA after chemoembolization for hepatocellular carcinoma and the efficacy of antiviral treatment[J]. Dig Dis Sci, 2016, 61(9): 2465-2476. DOI: 10.1007/s10620-016-4167-5
    [7]
    PIETRO L, KOSH A THOMAS B, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021
    [8]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.12.007

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007
    [9]
    LIU WP, XIAO XB, XUE M, et al. Prophylactic use of entecavir for lymphoma patients with past hepatitis B virus infection: A randomized controlled trial[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(2): 103-108. DOI: 10.1016/j.clml.2018.11.008
    [10]
    National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology: Hepatobiliary cancers (2012)[EB/OL].https://www.nccn.org/.
    [11]
    YEO W, JOHNSON PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy[J]. Hepatology, 2006, 43(2): 209-220. DOI: 10.1002/hep.21051/full
    [12]
    LAO XM, LUO G, YE LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J]. Liver Int, 2013, 33(4): 595-604. DOI: 10.1111/liv.12112
    [13]
    YU LH, LI N, SHI J, et al. Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?[J]. Ann Surg Oncol, 2014, 21(3): 1010-1015. DOI: 10.1245/s10434-013-3320-z
    [14]
    KUSUMOTO S, ARCAINI L, HONG X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. Blood, 2019, 133(2): 137-146. DOI: 10.1182/blood-2018-04-848044
    [15]
    PARK JW, PARK KW, CHO SH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: Report of a prospective study[J]. Am J Gastroenterol, 2005, 100(10): 2194-2200. DOI: 10.1111/j.1572-0241.2005.00232.x
    [16]
    LIAO Y, WANG B, HUANG ZL, et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage Ⅲ hepatocellular carcinoma: A prospective study[J]. PLoS One, 2013, 8(4): e60444. DOI: 10.1371/journal.pone.0060444
    [17]
    LAO XM, LUO G, YE LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J]. Liver Int, 2013, 33(4): 595-604. DOI: 10.1111/liv.12112
    [18]
    JIANG E, SHANGGUAN AJ, CHEN S, et al. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma[J]. Cancer Lett, 2016, 379(2): 262-267. DOI: 10.1016/j.canlet.2015.07.016
    [19]
    HEIMBACH JK, KULIK LM, FINN RS, et al, AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (417) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return